ADICET BIO INC's ticker is ACET and the CUSIP is 007002108. A total of 55 filers reported holding ADICET BIO INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,401,332 | -43.6% | 8,322,140 | 0.0% | 0.24% | -33.9% |
| Q2 2023 | $20,222,800 | -52.9% | 8,322,140 | +11.7% | 0.37% | -56.5% |
| Q1 2023 | $42,895,526 | -35.6% | 7,447,140 | 0.0% | 0.84% | -33.9% |
| Q4 2022 | $66,577,432 | -37.1% | 7,447,140 | 0.0% | 1.27% | -35.2% |
| Q3 2022 | $105,898,000 | -2.6% | 7,447,140 | -0.0% | 1.97% | -0.2% |
| Q2 2022 | $108,728,000 | -26.9% | 7,447,141 | 0.0% | 1.97% | -18.3% |
| Q1 2022 | $148,719,000 | +14.2% | 7,447,141 | 0.0% | 2.41% | +44.0% |
| Q4 2021 | $130,250,000 | +129.7% | 7,447,141 | +3.0% | 1.67% | +168.7% |
| Q3 2021 | $56,706,000 | -23.8% | 7,232,856 | 0.0% | 0.62% | -17.3% |
| Q2 2021 | $74,426,000 | -21.3% | 7,232,856 | 0.0% | 0.75% | -14.9% |
| Q1 2021 | $94,606,000 | +0.4% | 7,232,856 | +7.8% | 0.88% | +7.3% |
| Q4 2020 | $94,255,000 | +18.2% | 6,708,507 | 0.0% | 0.82% | -17.7% |
| Q3 2020 | $79,764,000 | – | 6,708,507 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 1,615,385 | $20,968,000 | 7.24% |
| Consonance Capital Management LP | 1,216,860 | $15,917,000 | 1.70% |
| VR Adviser, LLC | 1,000,000 | $13,080,000 | 1.42% |
| Johnson & Johnson Innovation - JJDC, Inc. | 728,944 | $9,535,000 | 1.24% |
| DAFNA Capital Management LLC | 385,077 | $5,037,000 | 1.20% |
| Ally Bridge Group (NY) LLC | 425,000 | $5,559,000 | 1.07% |
| Orbimed Advisors | 7,232,856 | $94,606,000 | 0.88% |
| Avidity Partners Management LP | 2,230,000 | $29,168,000 | 0.81% |
| Altium Capital Management LP | 142,289 | $1,861,000 | 0.52% |
| Nantahala Capital Management | 395,875 | $5,178,000 | 0.15% |